PDE4: Recent Medicinal Chemistry Strategies to Mitigate Adverse Effects

Phosphodiesterases and Their Inhibitors

Volumn 61, Issue , 2014, Pages 45-64

  Darout, Etzer ^a   Menhaji Klotz, Elnaz ^a   Chappie, Thomas A ^a  

^a PFIZER INC   (United States)

Author keywords

Apremilast; Cilomilast; Gastrointestinal effects; Phosphodiesterase; Roflumilast; Rolipram

Indexed keywords

APREMILAST; CILOMILAST; GASTROINTESTINAL EFFECTS; PHOSPHODIESTERASES; ROFLUMILAST; ROLIPRAM;

ESTERS;

EID: 84911862557     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527682348.ch04     Document Type: Chapter

References (71)

1. Francis, S.H., Conti, M., and Houslay, M.D. (2011) Handbook of Experimental Pharmacology #204: Phosphodiesterases as Drug Targets, Springer, Berlin.
2. Bolger, G. et al. (1993) A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs. Molecular and Cellular Biology, 13, 6558-6571.
3. Press, N.J. and Banner, K.H. (2009) Progress in Medicinal Chemistry (eds. G. Lawton and D.R.W. Lawton), Elsevier, Amsterdam.
4. Houslay, M.D., Schafer, P., and Zhang, K.Y. (2005) Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discovery Today, 10, 1503-1519.
5. Spina, D. (2008) PDE4 inhibitors: current status. British Journal of Pharmacology, 155, 308-315.
6. Zhang, K.Y., Ibrahim, P.N., Gillette, S., and Bollag, G. (2005) Phosphodiesterase-4 as a potential drug target. Expert Opinion on Therapeutic Targets, 9, 1283-1305.
7. Houslay, M.D. and Adams, D.R. (2003) PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. The Biochemical Journal, 370, 1-18.
8. Cheng, A.C. et al. (2007) Structure-based maximal affinity model predicts smallmolecule druggability. Nature Biotechnology, 25, 71-75.
9. Rabe, K.F. (2011) Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. British Journal of Pharmacology, 163, 53-67.
10. Boswell-Smith, V., Spina, D., and Page, C.P. (2006) Phosphodiesterase inhibitors. British Journal of Pharmacology, 147, S252-S257.
11. Wang, C. et al. (2012) The phosphodiesterase-4 inhibitor rolipram reverses Ab-induced cognitive impairment and neuroinflammatory and apoptotic responses in rats. The International Journal of Neuropsychopharmacology, 15, 749-766.
12. Zhu, J., Mix, E., and Winblad, B. (2001) The antidepressant and antiinflammatory effects of rolipram in the central nervous system. CNS Drug Reviews, 7, 387-398.
13. Chen, T.C. et al. (2002) The type IV phosphodiesterase inhibitor rolipram induces expression inhibitors p21Cip1 and p27Kip1, resulting in growth inhibition, increased differentiation, and subsequent apoptosis of malignant A-172 glioma cells. Cancer Biology & Therapy, 1, 268-276.
14. Card, G.L. et al. (2004) Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure (London, England:1993), 12, 2233-2247.
15. Barnette, M.S. et al. (1995) Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site. The Journal of Pharmacology and Experimental Therapeutics, 273, 1396-1402.
16. Duplantier, A.J. et al. (1996) Biarylcarboxylic acids and-amides: inhibition of phosphodiesterase type IV versus [3H] rolipram binding activity and their relationship to emetic behavior in the ferret. Journal of Medicinal Chemistry, 39, 120-125.
17. Amschler, H. et al. (1995) Fluoroalkoxysubstituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors. WO199501338 (to Byk Gulden Lomberg Chemische Fabrik GmbH).
18. Hatzelmann, A. et al. (2010) The preclinical pharmacology of roflumilast: a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulmonary Pharmacology & Therapeutics, 23, 235-256.
19. Bethke, T.D. et al. (2007) Dose-proportional intraindividual single-and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor. The Journal of Clinical Pharmacology, 47, 26-36.
20. Catafau, A. et al. (2008) Pharmacokinetics and time-course of D2 receptor occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. Journal of Psychopharmacology, 22, 882-894.
21. Tenor, H. et al. (2011) Pharmacology, clinical efficacy, and tolerability of phosphodiesterase-4 inhibitors: impact of human pharmacokinetics. Handbook of Experimental Pharmacology, 204, 85-119.
22. Stănescu, D. et al. (1996) Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax, 51, 267-271.
23. Calverley, P.M.A. et al. (2009) Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. The Lancet, 374, 685-694.
24. Boswell-Smith, V., Cazzola, M., and Page, C. P. (2006) Are phosphodiesterase 4 inhibitors just more theophylline? The Journal of Allergy and Clinical Immunology, 117, 1237-1243.
25. Wouters, E.F.M. et al. (2012) Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus. Journal of Clinical Endocrinology & Metabolism, 97, E1720-E1725.
26. Barnette, M.S. et al. (1998) SB 207499 (Ariflo), a potent and selective secondgeneration phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. The Journal of Pharmacology and Experimental Therapeutics, 284, 420-426.
27. Aoki, M. et al. (2001) Studies on mechanisms of low emetogenicity of YM976, a novel phosphodiesterase type 4 inhibitor. The Journal of Pharmacology and Experimental Therapeutics, 298, 1142-1149.
28. Gamble, E. et al. (2003) Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine, 168, 976-982.
29. Rennard, S. et al. (2008) The efficacy and safety of cilomilast in COPD. Drugs, 68 (Suppl. 2), 3-57.
30. Martina, S.D., Ismail, M.S., and Vesta, K.S. (2006) Cilomilast: orally active selective phosphodiesterase-4 inhibitor for treatment of chronic obstructive pulmonary disease. Annals of Pharmacotherapy, 40, 1822-1828.
31. Schett, G., Sloan, V.S., Stevens, R.M., and Schafer, P. (2010) Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases. Therapeutic Advances in Musculoskeletal Disease, 2, 271-278.
32. Schafer, P.H., Muller, G.W., Man, H.-W., and Ge, C. (2003) (Celgene Corporation). Methods of Using (+)-2-Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione. WO2003080049.
33. Schafer, P.H. et al. (2010) Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. British Journal of Pharmacology, 159, 842-855.
34. Burgin, A.B. et al. (2010) Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nature Biotechnology, 28, 63-70.
35. Saldou, N. et al. (1998) Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors. Cellular Signalling, 10, 427-440.
36. Souness, J.E., and Rao, S. (1997) Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cellular Signalling, 9, 227-236.
37. Jacobitz, S., McLaughlin, M.M., Livi, G.P., Burman, M., and Torphy, T.J. (1996) Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding. Molecular Pharmacology, 50, 891-899.
38. Rocque,W.J. et al. (1997) Human recombinant phosphodiesterase 4B2B binds (R)-rolipram at a single site with two affinities. Biochemistry, 36, 14250-14261.
39. Sarter, M., Bodewitz, G., and Stephens, D. (1988) Attenuation of scopolamine-induced impairment of spontaneous alternation behaviour by antagonist but not inverse agonist and agonist b-carbolines. Psychopharmacology, 94, 491-495.
40. Robichaud, A. et al. (2002) Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. The Journal of Clinical Investigation, 110, 1045-1052.
41. Robichaud, A. et al. (2002) Assessing the emetic potential of PDE4 inhibitors in rats. British Journal of Pharmacology, 135, 113-118.
42. Giorgi, M., Modica, A., Pompili, A., Pacitti, C., and Gasbarri, A. (2004) The induction of cyclic nucleotide phosphodiesterase 4 gene (PDE4D) impairs memory in a water maze task. Behavioural Brain Research, 154, 99-106.
43. Li, Y.-F. et al. (2011) Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling. The Journal of Neuroscience, 31, 172-183.
44. Zhang, H.T. et al. (2002) Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology, 27, 587-595.
45. Müller, T., Engels, P., and Fozard, J.R. (1996) Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition. Trends in Pharmacological Sciences, 17, 294-298.
46. Souness, J.E. et al. (1995) Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMPspecific phosphodiesterase: comparison with rolipram. British Journal of Pharmacology, 115, 39-46.
47. Bousquet, J. et al. (1990) Eosinophilic inflammation in asthma. The New England Journal of Medicine, 323, 1033-1039.
48. Marfat, A. and Chambers, R.J. (1998) Nicotinamide derivatives WO1998045268 (to Pfizer Inc.).
49. Kalgutkar, A.S., Choo, E., Taylor, T.J., and Marfat, A. (2004) Disposition of CP-671, 305, a selective phosphodiesterase 4 inhibitor in preclinical species. Xenobiotica; The Fate of Foreign Compounds in Biological Systems, 34, 755-770.
50. Hersperger, R. (1998) Preparation of 8-aryl-1,7-naphthyridines as antiinflammatories and antiasthmatics WO199818796 (to Novartis A.-G.).
51. Hersperger, R., Dawson, J., and Mueller, T. (2002) Synthesis of 4-(8-benzo[1,2,5] oxadiazol-5-yl-[1,7]naphthyridine-6-yl)-benzoic acid: a potent and selective phosphodiesterase type 4D inhibitor. Bioorganic & Medicinal Chemistry Letters, 12, 233-235.
52. Trifilieff, A., Wyss, D., Walker, C., Mazzoni, L., and Hersperger, R. (2002) Pharmacological profile of a novel phosphodiesterase 4 inhibitor, 4-(8-benzo [1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-yl)-benzoic acid (NVP-ABE171), a 1,7-naphthyridine derivative, with antiinflammatory activities. The Journal of Pharmacology and Experimental Therapeutics, 301, 241-248.
53. Aspiotis, R. et al. (2010) The discovery and synthesis of highly potent subtype selective phosphodiesterase 4D inhibitors. Bioorganic & Medicinal Chemistry Letters, 20, 5502-5505.
54. Liu, S. et al. (2005) Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors. Journal of Pharmacology and Experimental Therapeutics, 314, 846-854.
55. Lehnart, S.E. and Marks, A.R. (2006) Phosphodiesterase 4D and heart failure: a cautionary tale. Expert Opinion on Therapeutic Targets, 10, 677-688.
56. Bruno, O. et al. (2009) New selective phosphodiesterase 4D inhibitors differently acting on long, short, and supershort isoforms. Journal of Medicinal Chemistry, 52, 6546-6557.
57. Bruno, O. et al. (2011) GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses. British Journal of Pharmacology, 164, 2054-2063.
58. Jin, S.-L.C., Lan, L., Zoudilova, M., and Conti, M. (2005) Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. The Journal of Immunology, 175, 1523-1531.
59. Naganuma, K. et al. (2009) Discovery of selective PDE4B inhibitors. Bioorganic & Medicinal Chemistry Letters, 19, 3174-3176.
60. Kranz, M. et al. (2009) Identification of PDE4B over 4D subtype-selective inhibitors revealing an unprecedented binding mode. Bioorganic & Medicinal Chemistry, 17, 5336-5341.
61. Xu, R.X. et al. (2000) Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. Science, 288, 1822-1825.
62. Donnell, A.F. et al. (2010) Identification of pyridazino[4,5-b]indolizines as selective PDE4B inhibitors. Bioorganic & Medicinal Chemistry Letters, 20, 2163-2167.
63. Woodrow, M.D. et al. (2009) Quinolines as a novel structural class of potent and selective PDE4 inhibitors: optimisation for inhaled administration. Bioorganic & Medicinal Chemistry Letters, 19, 5261-5265.
64. Tralau-Stewart, C.J. et al. (2011) GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization. The Journal of Pharmacology and Experimental Therapeutics, 337, 145-154.
65. Akama, T. et al. (2009) Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorganic & Medicinal Chemistry Letters, 19, 2129-2132.
66. Freund, Y.R. et al. (2012) Boron-based phosphodiesterase inhibitors show novel binding of boron to PDE4 bimetal center. FEBS Letters, 586, 3410-3414.
67. Phillips, G. and Salmon, M. (2012) Annual Reports in Medicinal Chemistry (ed. C.D. Manoj), Academic Press, pp. 209-221.
68. Poondra, R.R. et al. (2013) Discovery of novel 1,4-dihydropyridine-based PDE4 inhibitors. Bioorganic & Medicinal Chemistry Letters, 23, 1104-1109.
69. Hulme, C. et al. (1998) The synthesis and biological evaluation of a novel series of indole PDE4 inhibitors I. Bioorganic & Medicinal Chemistry Letters, 8, 1867-1872.
70. Kobayashi, M. et al. (2011) ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity. International Immunopharmacology, 11, 732-739.
71. Mori, F. et al. (2010) The human area postrema and other nuclei related to the emetic reflex express cAMP phosphodiesterases 4B and 4D. Journal of Chemical Neuroanatomy, 40, 36-42.